Coexpression cluster:C1337: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{ | |||
Latest revision as of 11:42, 17 September 2013
Full id: C1337_Burkitt_CD19_lymphoma_diffuse_acute_tonsil_appendix
Phase1 CAGE Peaks
Hg19::chr11:2406614..2406631,+ | p17@CD81 |
Hg19::chr11:2415061..2415109,+ | p20@CD81 |
Hg19::chr11:64900193..64900215,+ | p@chr11:64900193..64900215 + |
Hg19::chr15:89182587..89182600,+ | p11@ISG20 |
Hg19::chr3:32001842..32001868,- | p5@OSBPL10 |
Hg19::chr9:95824637..95824655,+ | p@chr9:95824637..95824655 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
No results for this coexpression
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0043128 | positive regulation of 1-phosphatidylinositol 4-kinase activity | 0.00307311903920876 |
GO:0008310 | single-stranded DNA specific 3'-5' exodeoxyribonuclease activity | 0.00307311903920876 |
GO:0043126 | regulation of 1-phosphatidylinositol 4-kinase activity | 0.00307311903920876 |
GO:0046813 | virion attachment, binding of host cell surface receptor | 0.00307311903920876 |
GO:0008859 | exoribonuclease II activity | 0.00307311903920876 |
GO:0008297 | single-stranded DNA specific exodeoxyribonuclease activity | 0.00512171429365841 |
GO:0008296 | 3'-5'-exodeoxyribonuclease activity | 0.00552014538017045 |
GO:0019062 | virion attachment to host cell surface receptor | 0.00552014538017045 |
GO:0051704 | multi-organism process | 0.00552014538017045 |
GO:0000738 | DNA catabolic process, exonucleolytic | 0.0061456953109873 |
GO:0006661 | phosphatidylinositol biosynthetic process | 0.00768053622240581 |
GO:0043550 | regulation of lipid kinase activity | 0.00768053622240581 |
GO:0016895 | exodeoxyribonuclease activity, producing 5'-phosphomonoesters | 0.00768053622240581 |
GO:0004529 | exodeoxyribonuclease activity | 0.00768053622240581 |
GO:0044409 | entry into host | 0.00768053622240581 |
GO:0030260 | entry into host cell | 0.00768053622240581 |
GO:0019059 | initiation of viral infection | 0.00768053622240581 |
GO:0052192 | movement in environment of other organism during symbiotic interaction | 0.00768053622240581 |
GO:0046718 | entry of virus into host cell | 0.00768053622240581 |
GO:0052126 | movement in host environment | 0.00768053622240581 |
GO:0051828 | entry into other organism during symbiotic interaction | 0.00768053622240581 |
GO:0051806 | entry into cell of other organism during symbiotic interaction | 0.00768053622240581 |
GO:0000175 | 3'-5'-exoribonuclease activity | 0.00801423663574463 |
GO:0016896 | exoribonuclease activity, producing 5'-phosphomonoesters | 0.00904943320919911 |
GO:0004532 | exoribonuclease activity | 0.00904943320919911 |
GO:0016605 | PML body | 0.00904943320919911 |
GO:0008283 | cell proliferation | 0.00904943320919911 |
GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 0.00904943320919911 |
GO:0044255 | cellular lipid metabolic process | 0.00904943320919911 |
GO:0016796 | exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 0.0106295800771421 |
GO:0051701 | interaction with host | 0.0106295800771421 |
GO:0042327 | positive regulation of phosphorylation | 0.0106295800771421 |
GO:0045937 | positive regulation of phosphate metabolic process | 0.0106295800771421 |
GO:0046488 | phosphatidylinositol metabolic process | 0.0106295800771421 |
GO:0006629 | lipid metabolic process | 0.0106295800771421 |
GO:0001934 | positive regulation of protein amino acid phosphorylation | 0.0106295800771421 |
GO:0033240 | positive regulation of amine metabolic process | 0.0106295800771421 |
GO:0008408 | 3'-5' exonuclease activity | 0.0106295800771421 |
GO:0045764 | positive regulation of amino acid metabolic process | 0.0106295800771421 |
GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 0.0107473700634525 |
GO:0044403 | symbiosis, encompassing mutualism through parasitism | 0.0116964400431298 |
GO:0044419 | interspecies interaction between organisms | 0.0116964400431298 |
GO:0046489 | phosphoinositide biosynthetic process | 0.0122104034369311 |
GO:0006308 | DNA catabolic process | 0.0122104034369311 |
GO:0018108 | peptidyl-tyrosine phosphorylation | 0.0138408135504591 |
GO:0018212 | peptidyl-tyrosine modification | 0.0138408135504591 |
GO:0001932 | regulation of protein amino acid phosphorylation | 0.0138408135504591 |
GO:0046474 | glycerophospholipid biosynthetic process | 0.0138408135504591 |
GO:0033238 | regulation of amine metabolic process | 0.0138408135504591 |
GO:0006401 | RNA catabolic process | 0.0138408135504591 |
GO:0006521 | regulation of amino acid metabolic process | 0.0138408135504591 |
GO:0019058 | viral infectious cycle | 0.0144749454686281 |
GO:0004536 | deoxyribonuclease activity | 0.0144749454686281 |
GO:0000187 | activation of MAPK activity | 0.0158981075577646 |
GO:0022415 | viral reproductive process | 0.0158981075577646 |
GO:0042325 | regulation of phosphorylation | 0.0175281333520275 |
GO:0043406 | positive regulation of MAP kinase activity | 0.0177577205244823 |
GO:0051174 | regulation of phosphorus metabolic process | 0.017933986465953 |
GO:0019220 | regulation of phosphate metabolic process | 0.017933986465953 |
GO:0004527 | exonuclease activity | 0.0184002034618907 |
GO:0030384 | phosphoinositide metabolic process | 0.0201047733179097 |
GO:0051247 | positive regulation of protein metabolic process | 0.0210136885862123 |
GO:0008654 | phospholipid biosynthetic process | 0.0222677156438762 |
GO:0043405 | regulation of MAP kinase activity | 0.0222677156438762 |
GO:0009615 | response to virus | 0.0230949428438987 |
GO:0004540 | ribonuclease activity | 0.0230949428438987 |
GO:0006650 | glycerophospholipid metabolic process | 0.0230949428438987 |
GO:0016604 | nuclear body | 0.024327393602476 |
GO:0046467 | membrane lipid biosynthetic process | 0.0250810723586737 |
GO:0018193 | peptidyl-amino acid modification | 0.026466815327271 |
GO:0006869 | lipid transport | 0.0291011781757484 |
GO:0045860 | positive regulation of protein kinase activity | 0.0299671166871473 |
GO:0033674 | positive regulation of kinase activity | 0.0299873162667024 |
GO:0030145 | manganese ion binding | 0.0299873162667024 |
GO:0051347 | positive regulation of transferase activity | 0.0299873162667024 |
GO:0000165 | MAPKKK cascade | 0.0301940094590606 |
GO:0051707 | response to other organism | 0.0408603841728031 |
GO:0006644 | phospholipid metabolic process | 0.0420876339425699 |
GO:0008202 | steroid metabolic process | 0.0430909364360579 |
GO:0008284 | positive regulation of cell proliferation | 0.0444473594883361 |
GO:0045859 | regulation of protein kinase activity | 0.0446469816440654 |
GO:0043549 | regulation of kinase activity | 0.0448557680711419 |
GO:0004518 | nuclease activity | 0.0448557680711419 |
GO:0051338 | regulation of transferase activity | 0.0448557680711419 |
GO:0043085 | positive regulation of catalytic activity | 0.0459310451268304 |
GO:0006643 | membrane lipid metabolic process | 0.0482115020772507 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
lymphocyte of B lineage | 8.56e-83 | 24 |
pro-B cell | 8.56e-83 | 24 |
B cell | 5.47e-75 | 14 |
lymphocyte | 1.03e-39 | 53 |
common lymphoid progenitor | 1.03e-39 | 53 |
nucleate cell | 3.97e-38 | 55 |
lymphoid lineage restricted progenitor cell | 3.08e-36 | 52 |
precursor B cell | 2.75e-19 | 3 |
nongranular leukocyte | 5.19e-16 | 115 |
mature B cell | 1.12e-13 | 2 |
pre-B-II cell | 1.12e-13 | 2 |
transitional stage B cell | 1.12e-13 | 2 |
small pre-B-II cell | 1.12e-13 | 2 |
immature B cell | 1.12e-13 | 2 |
hematopoietic lineage restricted progenitor cell | 1.91e-13 | 120 |
leukocyte | 5.90e-13 | 136 |
hematopoietic oligopotent progenitor cell | 2.36e-10 | 161 |
hematopoietic multipotent progenitor cell | 2.36e-10 | 161 |
hematopoietic stem cell | 9.16e-10 | 168 |
angioblastic mesenchymal cell | 9.16e-10 | 168 |
hematopoietic cell | 4.48e-09 | 177 |
B-1 B cell | 6.80e-08 | 1 |
antibody secreting cell | 1.80e-07 | 1 |
plasma cell | 1.80e-07 | 1 |
plasmablast | 1.80e-07 | 1 |
Ontology term | p-value | n |
---|---|---|
hemopoietic organ | 4.27e-14 | 7 |
immune organ | 4.27e-14 | 7 |
spleen | 3.39e-09 | 3 |
gastrointestinal system mesentery | 3.39e-09 | 3 |
stomach region | 3.39e-09 | 3 |
mesentery | 3.39e-09 | 3 |
gastrointestinal system serosa | 3.39e-09 | 3 |
mesentery of stomach | 3.39e-09 | 3 |
gut mesentery | 3.39e-09 | 3 |
dorsal mesentery | 3.39e-09 | 3 |
dorsal mesogastrium | 3.39e-09 | 3 |
peritoneal cavity | 3.39e-09 | 3 |
spleen primordium | 3.39e-09 | 3 |
tonsil | 1.01e-07 | 1 |
mucosa-associated lymphoid tissue | 1.01e-07 | 1 |
lymphoid tissue | 1.01e-07 | 1 |
tonsillar ring | 1.01e-07 | 1 |
vermiform appendix | 1.07e-07 | 1 |
caecum | 1.07e-07 | 1 |
midgut | 1.07e-07 | 1 |
submandibular gland | 1.58e-07 | 1 |
submandibular gland primordium | 1.58e-07 | 1 |
thymus | 6.86e-07 | 4 |
hemolymphoid system gland | 6.86e-07 | 4 |
thymic region | 6.86e-07 | 4 |
pharyngeal gland | 6.86e-07 | 4 |
thymus primordium | 6.86e-07 | 4 |
Ontology term | p-value | n |
---|---|---|
lymphoma | 9.06e-11 | 10 |
lymphatic system cancer | 6.80e-08 | 1 |
lymphosarcoma | 6.80e-08 | 1 |
acute leukemia | 1.22e-07 | 1 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
MA0003.1 | 0.321379 |
MA0004.1 | 0.558729 |
MA0006.1 | 0.391183 |
MA0007.1 | 1.33289 |
MA0009.1 | 1.03681 |
MA0014.1 | 0.108006 |
MA0017.1 | 1.10421 |
MA0019.1 | 0.7124 |
MA0024.1 | 0.929647 |
MA0025.1 | 1.17262 |
MA0027.1 | 2.65688 |
MA0028.1 | 0.408079 |
MA0029.1 | 0.949428 |
MA0030.1 | 0.937696 |
MA0031.1 | 0.871496 |
MA0038.1 | 0.665566 |
MA0040.1 | 0.955415 |
MA0041.1 | 0.578072 |
MA0042.1 | 0.544748 |
MA0043.1 | 1.03713 |
MA0046.1 | 1.02569 |
MA0048.1 | 0.906394 |
MA0050.1 | 0.545671 |
MA0051.1 | 0.661179 |
MA0052.1 | 0.959373 |
MA0055.1 | 1.71708 |
MA0056.1 | 0 |
MA0057.1 | 0.882847 |
MA0058.1 | 0.458909 |
MA0059.1 | 0.457555 |
MA0060.1 | 0.267412 |
MA0061.1 | 1.93637 |
MA0063.1 | 0 |
MA0066.1 | 0.66601 |
MA0067.1 | 1.35893 |
MA0068.1 | 0.199491 |
MA0069.1 | 1.02175 |
MA0070.1 | 1.01032 |
MA0071.1 | 0.625297 |
MA0072.1 | 1.00572 |
MA0073.1 | 3.04208 |
MA0074.1 | 0.660398 |
MA0076.1 | 0.475586 |
MA0077.1 | 0.997832 |
MA0078.1 | 0.763954 |
MA0081.1 | 0.457725 |
MA0083.1 | 1.04447 |
MA0084.1 | 1.5477 |
MA0087.1 | 1.00322 |
MA0088.1 | 0.0971959 |
MA0089.1 | 0 |
MA0090.1 | 0.490736 |
MA0091.1 | 0.561458 |
MA0092.1 | 0.522012 |
MA0093.1 | 0.394379 |
MA0095.1 | 0 |
MA0098.1 | 0 |
MA0100.1 | 0.679972 |
MA0101.1 | 1.02896 |
MA0103.1 | 1.76074 |
MA0105.1 | 0.419295 |
MA0106.1 | 0.70837 |
MA0107.1 | 0.857383 |
MA0108.2 | 0.868347 |
MA0109.1 | 0 |
MA0111.1 | 0.504913 |
MA0113.1 | 0.725375 |
MA0114.1 | 0.845337 |
MA0115.1 | 1.28169 |
MA0116.1 | 0.865577 |
MA0117.1 | 1.07516 |
MA0119.1 | 0.440684 |
MA0122.1 | 1.10154 |
MA0124.1 | 1.23968 |
MA0125.1 | 1.15445 |
MA0130.1 | 0 |
MA0131.1 | 0.782708 |
MA0132.1 | 0 |
MA0133.1 | 0 |
MA0135.1 | 1.06778 |
MA0136.1 | 0.672893 |
MA0139.1 | 0.226048 |
MA0140.1 | 0.622527 |
MA0141.1 | 0.455728 |
MA0142.1 | 0.838805 |
MA0143.1 | 0.725558 |
MA0144.1 | 0.299851 |
MA0145.1 | 0.107156 |
MA0146.1 | 0.718193 |
MA0147.1 | 0.87383 |
MA0148.1 | 0.584698 |
MA0149.1 | 0.612449 |
MA0062.2 | 0.23336 |
MA0035.2 | 0.621793 |
MA0039.2 | 0.35955 |
MA0138.2 | 0.765223 |
MA0002.2 | 0.255126 |
MA0137.2 | 0.414885 |
MA0104.2 | 0.735746 |
MA0047.2 | 0.695777 |
MA0112.2 | 0.332548 |
MA0065.2 | 1.7308 |
MA0150.1 | 0.484557 |
MA0151.1 | 0 |
MA0152.1 | 0.629368 |
MA0153.1 | 1.13732 |
MA0154.1 | 0.819655 |
MA0155.1 | 0.318517 |
MA0156.1 | 0.417278 |
MA0157.1 | 0.810597 |
MA0158.1 | 0 |
MA0159.1 | 0.328286 |
MA0160.1 | 0.600559 |
MA0161.1 | 0 |
MA0162.1 | 0.0383129 |
MA0163.1 | 0.813808 |
MA0164.1 | 0.738243 |
MA0080.2 | 1.02158 |
MA0018.2 | 0.709805 |
MA0099.2 | 0.629739 |
MA0079.2 | 0.476723 |
MA0102.2 | 1.58513 |
MA0258.1 | 0.289793 |
MA0259.1 | 0.336472 |
MA0442.1 | 0 |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)
TF | #promoters | Enrichment | p-value | q-value |
---|---|---|---|---|
MEF2C#4208 | 2 | 13.7704514975413 | 0.00823559694227006 | 0.0324646149714555 |
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.